SCHEMBL3245767

SCHEMBL3245767

CS(=O)(=O)c1ccc(Nc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
GAA P10253 2/20 0.58
PTGS2 P35354 4/20 0.56
HSD17B10 Q99714 2/20 0.56
ALDH1A1 P00352 2/20 0.56
ALOX12 P18054 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
PTGS1 P23219 1/20 0.56
SLC6A2 P23975 1/20 0.56
MAPK1 P28482 1/20 0.56
HTR2B P41595 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
GSK3B P49841 1/20 0.55
SNCA P37840 1/20 0.53
KDM1A O60341 2/20 0.53
HPGD P15428 2/20 0.52
GFER P55789 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25667539 0.91 ENPP2 (0.54) MEN1KMT2AGAAGSK3BATM
SCHEMBL20381932 0.82 ALDH1A1 (0.62) MEN1KMT2AGAAPTGS2HSD17B10
SCHEMBL2877698 0.81 GSK3B (0.59) PTGS2ALDH1A1PTGS1MAPK1TDP1
SCHEMBL9913187 0.80 PTGS2 (0.72) MEN1KMT2APTGS2ALDH1A1ALOX15
SCHEMBL5464915 0.80 CA1 (0.50) MEN1KMT2APTGS2
SCHEMBL24383402 0.79 ENPP2 (0.43) GSK3BATM
SCHEMBL5457984 0.79 ENPP2 (0.43) GSK3BATM
SCHEMBL4443489 0.78 ALDH1A1 (0.56) MEN1KMT2AGAAPTGS2HSD17B10
SCHEMBL540370 0.78 ALDH1A1 (0.56) MEN1KMT2AGAAPTGS2HSD17B10
SCHEMBL8023015 0.78 CA1 (0.67) MEN1KMT2APTGS2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024030000-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2024-02-08 WO disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
WO-2010012745-A2 BENZIMIDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-04 WO disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2007062797-A1 AMINO-SUBSTITUTED AZO-HETEROCYCLIC COMPOUNDS FOR TREATING INFLAMMATORY CONDITIONS 7TM PHARMA A/S (DK) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A MEN1 4426/4885KMT2A 1945/4885GAA 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.